Ligand completes merger, Pelthos to launch molluscum treatment

Ligand Pharmaceuticals (LGND) has completed a merger, establishing Pelthos Therapeutics Inc., which will commence trading as PTHS on NYSE American. Pelthos is set to launch ZELSUVMI, the first at-home prescription treatment for Molluscum contagiosum, in July, supported by $50.1 million in new equity capital, with Ligand retaining a 13% royalty on global sales. This strategic spin-off follows Ligand's strong Q1 2025 performance, where it surpassed adjusted EPS and revenue forecasts ($1.33 and $45 million respectively), underscoring its robust financial health and diversified portfolio poised for sustained growth amidst a challenging biotech financing environment.

Analysis

Ligand Pharmaceuticals (LGND) has strategically executed a merger to form Pelthos Therapeutics (PTHS), a new publicly traded entity focused on the commercialization of ZELSUVMI. This move crystallizes value for an asset while retaining significant upside for Ligand through a 13% royalty on worldwide sales. The launch of ZELSUVMI in July is a key catalyst, targeting the sizable Molluscum contagiosum market of approximately 16.7 million people in the U.S. with the first at-home prescription treatment. The new entity is well-capitalized for this launch, having secured $50.1 million in fresh equity, mitigating near-term financing risk in what is described as a challenging biotech funding environment. This transaction is underpinned by Ligand's robust financial health, evidenced by strong Q1 2025 results that surpassed analyst expectations with a 46% year-over-year revenue increase to $45 million and an adjusted EPS of $1.33. The company's confirmed full-year revenue guidance of $180-$200 million and its strong liquidity, reflected in a current ratio of 5.27, position it to capitalize on its diversified portfolio and royalty-based business model.

Key Decisions for Investors

• Investors in Ligand (LGND) should view this transaction as a positive de-risking event that provides a new, potentially high-margin royalty stream from ZELSUVMI without the associated commercialization costs, complementing its strong Q1 earnings and solid full-year guidance.
• For those considering the new entity, Pelthos (PTHS) represents a pure-play opportunity on the commercial success of ZELSUVMI; its performance will be highly dependent on the drug's market adoption and sales trajectory following the July launch.
• Monitor the initial sales figures for ZELSUVMI post-launch, as the success of this product is now a primary catalyst for realizing the value of Ligand's 13% royalty and will be the key driver for Pelthos's valuation.